Unicycive Therapeutics, Inc.
NASDAQ:UNCYBiotechnology
-$0.24 today
- Market cap
- $104.19M
- Beta
- 1.73
- P/E (TTM)
- -40.8
- EPS (TTM)
- -$0.17
Volume 1.39M
Average 0.65M
UNCY Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Unicycive Therapeutics, Inc.NASDAQ: UNCY
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt remains negative
Q1 FY2026 net debt was -$36.43M, compared with -$19.08M a year earlier.
Context
- Net debt amounted to 56.6% of total assets at the end of Q1 FY2026, down 11.7 pp from a year earlier.
- Net debt grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net debt keeps falling in the next quarterly balance sheet after a -91.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (29M) USD
- Year-over-year change
- -14.3%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (29M) | -14.3% |
| FY2024 | 2024-12-31 | (25.37M) | -185.4% |
| FY2023 | 2023-12-31 | (8.89M) | -3400.0% |
| FY2022 | 2022-12-31 | (254K) | +98.4% |
| FY2021 | 2021-12-31 | (16.24M) | — |
Net Debt vs competitors
How UNCY compares with its peers on the latest reported figures
- Peers report in different currencies, so net debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -91.0% is the 5th highest of 10, against a peer median of -134.2%.
- Net debt amounts to 56.6% of total assets for UNCY, versus a peer median of 45.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
CBUSCibus, Inc. | Mar 2026 | $245.83M USD | +1938.7% | +190.9% | 75.8% |
| Mar 2026 | -$9.78M USD | -750.3% | — | 4.2% | |
HYFTMindWalk Holdings Corp. | Jan 2026 | -CA$10.63M CAD | -81872.4% | — | 45.9% |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | -$31.65M USD | +11.2% | — | 29.4% |
| Mar 2026 | -$36.43M USD | -91.0% | — | 56.6% | |
| Mar 2026 | -$38.84M USD | +22.7% | — | 40.2% | |
| Mar 2026 | -$42.78M USD | -260.4% | — | 23.8% | |
| Mar 2026 | -$43.45M USD | -55.5% | — | 93.7% | |
| Mar 2026 | -$97.09M USD | -134.2% | — | 92.1% | |
| Mar 2026 | -$186.21M USD | -1297.0% | — | 98.1% | |
| Peer median (excluding UNCY) | — | -134.2% | +190.9% | 45.9% | |
Competitors are the stored peer set for UNCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
Intrinsic Alpha fair value
Locked
Current Price
$3.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.